Yingli Pharma Announces presentations on the Phase 1 trials of linperlisib, a PI3Kδ selective inhibitor, and YL-13027, an oral TGFβR1 inhibitor, at the American Society for Clinical Oncology 2021 …

<p xmlns=”https://www.w3.org/1999/xhtml”>Clinical trial data will be updated in three presentations on lead drug candidates <ul type=”disc” xmlns=”https://www.w3.org/1999/xhtml”><li><i>Linperlisib, a potent oral <span id=”spanHghlta68d”>PI3Kδ</i> <i>inhibitor, demonstrated robust clinical activity with 70% ORR in relapsed or refractory…